Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 43 |
| Active Pipeline (Recruiting Now) | 17 (7) |
| Completed vs Stopped Early | 23 / 3 (7.0%) |
| Median Closed Actual Enrollment | 71 participants |
| Physical Hospital Site Disclosure | 86.6% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Massachusetts General Hospital | Boston, MA | 8 |
| Columbia University Irving Medical Center | New York, NY | 7 |
| Oregon Health and Science University Knight Cancer Institute | Portland, OR | 7 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participa | Phase III | ACTIVE NOT RECRUITING |
| NCT05071300 | A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patien | Phase III | ACTIVE NOT RECRUITING |
| NCT05185843 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Tr | Phase III | ACTIVE NOT RECRUITING |
| NCT04849741 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) | Phase III | ACTIVE NOT RECRUITING |
| NCT05130450 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) | Phase III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Ionis Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.